- Home
- AIRI vs NRSN Comparison
AIRI vs NRSN Comparison
Compare AIRI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRI | NRSN |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 14.2M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIRI | NRSN |
|---|---|---|
| Price | $2.67 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 25.9K | ★ 472.2K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $0.25 |
| 52 Week High | $3.95 | $1.30 |
Technical Indicators
Market Signals| Indicator | AIRI | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 37.86 |
| Support Level | $2.55 | $0.25 |
| Resistance Level | $2.76 | $0.74 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 68.18 | 11.96 |
Price Performance
Historical ComparisonAbout AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.